Pinned Tweet
🥰Thank you so much @PennLPSOnline for celebrating this accomplishment! I am fortunate to be a small part of the UPenn family. Thank you for facilitating a challenging, accessible, and influential educational experience. Go Quakers! 💙❤️🤍
Kelley Roark, RMA retweeted
mTOR pathway gene knockout results in mTOR-dependent cellular aggregation
biorxiv.org/content/10.1101/… #aging #CellDeath #apoptosis #mTOR
Proud to share our new paper on BioRxiv! Check out the first author😎💅 #EpilepsyResearch #mTOR #cellbiology
mTOR pathway gene knockout results in mTOR-dependent cellular aggregation biorxiv.org/content/10.1101/…
Kelley Roark, RMA retweeted
I was sent this by a Georgian this morning. 2025 premiums vs 2026 premiums for someone making $65k a year.
Republicans in Washington did this.
This is what I'm fighting to stop. This is what’s at stake in this shutdown fight.
Kelley Roark, RMA retweeted
As a Norwegian-American, I must say I’m really sick of all this white supremacist Valhalla bullshit. Most Viking Age Norwegians were not cruising around in longships pillaging & blood-eagling their enemies, unless by that you mean growing barley, cod fishing, & herding sheep.
Kelley Roark, RMA retweeted
I don’t know who needs to hear this but Iron is a cofactor in making dopamine, serotonin, and norepinephrine. XO, Dr. Jen
Kelley Roark, RMA retweeted
Humility is not a lack of confidence. It's a lack of arrogance.
Arrogance says: I can do great things and you can't, so I'm better than you.
Confidence says: I can do great things and so can you, let's work together.
You can own your skills without diminishing those of others.
Kelley Roark, RMA retweeted
New findings in Science deepen our understanding of the role of membrane contact sites in cell biology and reactive oxygen species regulation.
📄: scim.ag/4mgAUuv
#SciencePerspective: scim.ag/46dmyX0
Kelley Roark, RMA retweeted
Scientists developed a way to engineer immune cells called T cells within a living organism. The approach could make CAR T cell therapies more accessible for treating cancer and autoimmune diseases. nih.gov/news-events/nih-rese…
ALT Illustration of a CAR T cell attacking a cancerous B cell. Credit: Nemes Laszlo / Shutterstock
My frontiers paper calls for controlled study & interdisciplinary dialogue. Predictably, biohacker enthusiasts read it as “anti off-label” or “anti-rapamycin.” The last sentence exposes biohacker bias against academics overall, demonstrating my point. 😊 fightaging.org/archives/2025…
Aging researchers have a responsibility to ensure their work isn’t misused. We need to foster more open conversations about how to prevent hype from distorting public understanding of science—especially as anti-establishment biohacking narratives increasingly shape the discourse.
I hope that helps address some key misunderstandings of the article as espoused by some of these faceless, yet highly passionate, Rapa-biohacker-devotees, as well as some wellness Medical Doctors who have shared my article without reading critically. 😊
rapamycin.news/t/rapamycin-f…
Thank you @Brainimmune for the opportunity to discuss our recent publication in @FrontAging. I hope this initiates dialogue across multiple disciplines for aging and epilepsy research. Rapamycin for Aging: Lessons in Biology, Ethics, and Scientific Rigor - brainimmune.com/rapamycin-fo…
Despite the hype, Rapamycin does, in fact, have quite a few pitfalls. Read more at: frontiersin.org/journals/agi…
On September 28th, I decided to stop rapamycin, ending almost 5 years of experimentation with this molecule for its longevity potential.
I have tested various rapamycin protocols including weekly (5, 6, and 10 mg dose schedules), biweekly (13 mg) and alternating weekly (6/13mg) to optimize rejuvenation and limit side effects.
Despite the immense potential from pre-clinical trials, my team and I came to the conclusion that the benefits of lifelong dosing of Rapamycin do not justify the hefty side-effects (intermittent skin/soft tissue infections, lipid abnormalities, glucose elevations, and increased resting heart rate). With no other underlying causes identified, we suspected Rapamycin, and since dosage adjustments had no effect, we decided to discontinue it entirely.
Preclinical and clinical research has indicated that prolonged rapamycin use can disrupt lipid metabolism and profiles [1], as well as induce insulin and glucose intolerance [2] as well as pancreatic Beta-cells toxicity [3]. Despite anecdotal evidence of rapamycin slowing down tumor growth, its effect in inhibiting natural killer cells [4] do raise concern for anti-cancer immune surveillance and cancer risk in the longer run.
Additionally, on October 27th, a new pre-print [5] indicated that Rapamycin was one of a handful of supposed longevity interventions to cause an increase/acceleration of aging in humans across 16 epigenetic aging clocks. This type of evaluation is the first of its kind, as most longevity interventions up to date have been tested against one or two aging clocks, leading to invisible biases and potential intended “cherry picking” of favorable clocks for the tested interventions.
Longevity research around these experimental compounds is constantly evolving, necessitating ongoing, close observation of the research and my biomarkers which my team and I do constantly.
Sources:
[1] pubmed.ncbi.nlm.nih.gov/1217…
[2]pmc.ncbi.nlm.nih.gov/article….
[3]diabetesjournals.org/diabete…
[4]pmc.ncbi.nlm.nih.gov/article….
Kelley Roark, RMA retweeted
Rapamycin for longevity: the pros, the cons, and future perspectives
frontiersin.org/journals/agi…
Super excited to share my very first, first author paper for an academic journal! This article also happens to be the very first publication out of Iffland Lab 🎉 #Rapamycin #mTOR #Aging #epilepsy #sirolimus
New Research: Rapamycin for longevity: the pros, the cons, and future perspectives frontiersin.org/articles/10.… #FrontiersIn #Aging